Current treatments for scabies
The DOI matches its Crossref record.
Abstract
Scabies is a frequent interhuman ectoparasitic infection. Several treatments are available worldwide. There are local treatments: synthetic pyrethrins, benzyl benzoate, lindane, crotamiton. Recently a few studies were published concerning ivermectin, systemic antiparasitic agent use in onchocercosis treatment. We reviewed the literature with an evidence‐based medicine method. We attempt to answer two questions in particular: what is the treatment of choice for common scabies in a patient otherwise in good health? What is the role of systemic ivermectin? We also report specific situations. Among local treatments, studies are heterogeneous according to products, countries, group of treated patients, with or without contact subjects, and the method of treatment application. There are very few high proof‐level controlled studies. In France, a combination of benzyl benzoate 10% and sulfiram 2% is used most, according to professional consensus. The most studied product is the cream permethrin 5%, available in the USA and UK. Its efficacy seems slightly superior to lindane and less toxic. It is more efficient than crotamiton. There is no study comparing benzyl benzoate and permethrin. Concerning systemic ivermectin, five controlled studies showed its efficiency in common scabies. But its relative efficiency over local treatment has not been established. A few open studies showed its efficacy in institutional epidemic, profuse scabies and in HIV‐positive patients. Local treatment of choice in common scabies remains to be determined among the four principal molecules. There is no study comparing permethrin or esdepallethrin to benzyl benzoate. In what cases should we prescribe crotamiton or lindane? Indication of ivermectin seems proved in common scabies and probably for HIV‐positive patients. It remains to be determined if it should be prescribed in the first instance, be double or triple, be associated or not with local treatment. In case of keratotic scabies, ivermectin seems interesting with two applications within 1 week, and should be associated with local treatment (duration remains to be defined). Ivermectin is probably useful in institutional epidemic, and therapeutic attitude remains to be defined. Ivermectin seems to have little or no risk. Treatment must be adapted case‐by‐case, according to feasibility. It is still important to treat contacts, and modality of this treatment remains to be specified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Heukelbach, J., & Feldmeier, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68772-2 · Cited by 338
Interventions for treating scabies
Strong, M., & Johnstone, P. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000320.pub2 · Cited by 315
Diagnosis, prevention, and treatment of scabies.
Shimose, L., & Munoz-Price, L. S. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0354-0 · Cited by 50
Efficacy, acceptability and cost effectiveness of four therapeutic agents for treatment of scabies.
Abdel-Raheem, T. A., Méabed, E. M. H., Nasef, G. A., Abdel Wahed, W. Y., & Rohaim, R. M. A. (2016) · Journal of Dermatological Treatment · doi:10.3109/09546634.2016.1151855 · Cited by 30
Metadata
- Authors
- Buffet, M., & Dupin, N.
- Venue
- Fundamental & Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2003-03-27
- Volume
- 17
- Issue
- 2
- Pages
- 217-225
- ISSN
- 0767-3981 (ISSN-L)
- 1472-8206
- OpenAlex
- W2007783562
- Cited by
- 82
- References
- 0
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current treatments for scabies. https://app.cochat.ai/papers/10.1046/j.1472-8206.2003.00173.x
- The paper
- Buffet, M., & Dupin, N. (2003). Current treatments for scabies. Fundamental & Clinical Pharmacology. https://doi.org/10.1046/j.1472-8206.2003.00173.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.